RPOT3 Antibody

What is RPL3 Antibody and what is its molecular target?

RPL3 antibody (such as 11005-1-AP) targets ribosomal protein L3, a critical component of the large ribosomal subunit involved in protein synthesis. The antibody is typically generated in rabbits and purified using antigen affinity techniques. The targeted protein has an observed molecular weight of approximately 46 kDa, though the calculated molecular weight can range from 46 to 27 kDa depending on processing and modifications . RPL3 is encoded by the RPL3 gene (NCBI Gene ID: 6122), and the protein has significant roles in ribosome assembly and function .

Ribosomal proteins like RPL3 are part of the complexes that catalyze protein synthesis and consist of both small 40S and large 60S subunits. Antibodies against these proteins are valuable for studying ribosome biogenesis, function, and related diseases.

What are the validated applications for RPL3 Antibody?

RPL3 antibody has been validated for multiple research applications, with documented performance in:

This range of applications makes the antibody versatile for multiple experimental approaches, enabling comprehensive study of RPL3 expression, localization, and interactions .

What are the recommended dilutions for each application technique?

Optimal dilution factors vary by application method. Following standardized protocols similar to those used for Midkine antibody characterization, these dilutions have been experimentally determined :

Note that these recommendations should serve as starting points for optimization in your specific experimental system. As with all antibodies, titration experiments are strongly recommended to determine optimal concentrations for your specific samples and detection methods .

What reactivity does RPL3 Antibody demonstrate with different species?

The RPL3 antibody shows documented reactivity with samples from specific species:

This cross-species reactivity makes the antibody valuable for comparative studies between human and mouse models. The conservation of ribosomal proteins across species explains this cross-reactivity pattern .

What are the proper storage conditions for maximizing RPL3 Antibody stability?

To maintain antibody functionality and prevent degradation, follow these evidence-based storage protocols:

• Store at -20°C for long-term preservation

• The antibody remains stable for one year after shipment when properly stored

• The liquid formulation contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3

• Aliquoting is unnecessary for -20°C storage, reducing freeze-thaw cycles

• Some preparations (20μl sizes) contain 0.1% BSA as a stabilizer

These storage conditions are similar to those recommended for other research antibodies, such as those used in SARS-CoV-2 research and OKT3 monoclonal antibodies .

How can I optimize Western Blot protocols for RPL3 Antibody?

For optimal Western Blot results with RPL3 antibody, implement these methodological refinements based on standardized protocols:

• Sample preparation: Prepare cell or tissue lysates in RIPA buffer with protease inhibitors; sonicate briefly to shear DNA and reduce sample viscosity.

• Protein quantification: Perform Bradford assay to ensure equal loading (typically 30μg protein per lane) .

• Gel selection: Use 10-20% gradient polyacrylamide gels for optimal separation of the 46 kDa RPL3 protein.

• Transfer optimization:

  • Transfer to nitrocellulose membranes (PVDF may also work)

  • Verify transfer efficiency with Ponceau staining

• Blocking and antibody incubation:

  • Block membranes with 5% milk in TBST for 1 hour at room temperature

  • Dilute RPL3 antibody in 5% BSA in TBST at 1:2000-1:16000

  • Incubate overnight at 4°C with gentle rocking

• Detection optimization:

  • For low abundance targets, use higher antibody concentrations and enhanced chemiluminescence detection

  • Consider signal amplification systems for extremely low expression levels

These methodological details are based on standardized protocols that have successfully detected RPL3 across multiple studies .

What are critical considerations for immunoprecipitation experiments using RPL3 Antibody?

When performing immunoprecipitation with RPL3 antibody, consider these methodological factors:

• Antibody-bead conjugation:

  • Use 1.0μg of RPL3 antibody per immunoprecipitation reaction

  • Pre-conjugate to protein A/G beads (follow manufacturer's protocol)

  • Allow sufficient conjugation time (2-4 hours at 4°C with rotation)

• Lysis buffer selection:

  • For studying RPL3 alone: Use RIPA buffer (more stringent, reduces non-specific binding)

  • For studying RPL3 complexes: Use NP-40 or Triton X-100 based buffers (gentler, preserves protein-protein interactions)

• Sample preparation optimization:

  • Input amount: Use 1.0-3.0 mg of total protein lysate

  • Pre-clear lysates with control IgG to reduce non-specific binding

  • Reserve 5-10% of lysate as input control

• Controls:

  • Include species-matched non-immune IgG control

  • Include a known positive control (e.g., lysate from cells expressing high levels of RPL3)

  • Include negative control (e.g., lysate from RPL3 knockdown cells if available)

• Detection methods:

  • Western blot with the same or different RPL3 antibody (different epitope)

  • Consider mass spectrometry for identifying novel interaction partners

These recommendations are based on successful immunoprecipitation protocols documented for ribosomal proteins and similar nuclear/cytoplasmic targets .

How should I troubleshoot non-specific binding in immunohistochemistry applications?

When encountering non-specific binding in IHC with RPL3 antibody, implement this systematic troubleshooting approach:

• Antigen retrieval optimization:

  • Primary recommendation: TE buffer pH 9.0

  • Alternative: Citrate buffer pH 6.0

  • Test both methods to determine optimal retrieval for your specific tissue

• Blocking optimization:

  • Increase blocking duration (1-2 hours)

  • Test different blocking agents (5% normal serum from same species as secondary antibody)

  • Include 0.1-0.3% Triton X-100 in blocking solution for better penetration

• Antibody dilution adjustment:

  • Start with 1:200 dilution and perform titration series (1:50, 1:100, 1:200, 1:500)

  • Incubate at 4°C overnight rather than shorter incubations at room temperature

• Washing optimization:

  • Increase wash duration and number of washes

  • Include 0.1% Tween-20 in wash buffer to reduce background

• Signal detection refinement:

  • Use amplification systems with caution (they can increase both signal and background)

  • For chromogenic detection, shorten substrate development time

  • For fluorescent detection, use Sudan Black B to quench tissue autofluorescence

These approaches are derived from standardized IHC troubleshooting protocols that have proven effective for nuclear/cytoplasmic proteins like RPL3 .

What validation strategies confirm RPL3 Antibody specificity in experimental contexts?

To validate RPL3 antibody specificity, implement these evidence-based approaches:

• Genetic validation:

  • siRNA/shRNA knockdown of RPL3 should reduce signal intensity

  • CRISPR/Cas9 knockout (where viable) provides definitive validation

  • This approach has been documented in published knockdown/knockout studies

• Recombinant protein controls:

  • Overexpression of tagged RPL3 should increase signal proportionally

  • Pre-absorption with recombinant RPL3 should diminish or eliminate specific signal

• Comparison with orthogonal methods:

  • Verify protein expression with RNA expression data (RT-qPCR)

  • Compare with mass spectrometry-based proteomics data

• Multi-antibody validation:

  • Test multiple antibodies against different RPL3 epitopes

  • Consistent staining patterns across antibodies suggest specificity

• Cross-species validation:

  • Test in samples from different species with known RPL3 conservation

  • Signal should correlate with evolutionary conservation of epitope

These validation approaches follow principles similar to those used for characterizing antibodies against SARS-CoV-2 and other targets, ensuring antibody specificity through multiple independent methods .

How does sample preparation influence RPL3 Antibody performance across applications?

Sample preparation significantly impacts RPL3 antibody performance in different applications:

• For Western Blot:

  • Fresh samples yield stronger signals than archived samples

  • Heat denaturation (95°C for 5 minutes) in Laemmli buffer with reducing agent is essential

  • Avoid repeated freeze-thaw cycles of prepared lysates

• For Immunohistochemistry:

  • Fixation protocol affects epitope availability:

    • 10% neutral-buffered formalin (24-48 hours) is standard

    • Overfixation can mask epitopes

  • Paraffin embedding versus frozen sections:

    • Paraffin requires more rigorous antigen retrieval

    • Frozen sections may preserve some epitopes better but have poorer morphology

• For Immunofluorescence:

  • Fixation method comparison:

    • 4% paraformaldehyde (10-15 minutes) preserves structure

    • Methanol fixation (-20°C, 10 minutes) may better expose some epitopes

  • Permeabilization optimization:

    • 0.1-0.3% Triton X-100 for nuclear proteins like RPL3

    • Saponin (0.1%) for gentler permeabilization

• For Immunoprecipitation:

  • Lysis buffer composition critically affects recovery:

    • NP-40 buffer: Better for preserving protein-protein interactions

    • RIPA buffer: More stringent, reduces background

  • Cell/tissue disruption method impacts yield:

    • Sonication releases nuclear proteins more effectively

    • Dounce homogenization is gentler for preserving complexes

These methodological considerations are based on experimental protocols that have yielded reproducible results with nuclear and ribosomal proteins .

How can I establish effective controls for validating RPL3 Antibody experimental results?

Implement these control strategies to ensure experimental validity when using RPL3 antibody:

• Essential negative controls:

  • Primary antibody omission control (all other steps identical)

  • Isotype control (non-specific IgG of same species/concentration)

  • Knockdown/knockout samples where RPL3 expression is reduced/eliminated

• Critical positive controls:

  • Samples with known high RPL3 expression (e.g., rapidly proliferating cells)

  • Recombinant RPL3 protein or RPL3-overexpressing cells

  • Tissues with established RPL3 expression patterns

• Loading and procedure controls:

  • For Western Blot: Housekeeping proteins (β-actin, GAPDH) and Ponceau staining

  • For IHC/IF: Internal control tissues/cells in the same section

  • For IP: Input sample (5-10% of lysate used for IP)

• Validation across techniques:

  • Confirm findings using orthogonal methods:

    • Protein detection (Western Blot) + localization (IF/IHC)

    • Protein-protein interactions (IP) + colocalization (IF)

• Quantification controls:

  • Include standard curves with known quantities of target protein

  • Use multiple biological and technical replicates

  • Employ statistical analysis appropriate for sample size

These control strategies align with antibody validation principles established for various research antibodies, including those used in studies of monoclonal antibodies like OKT3 and antiviral antibodies .

What future directions are emerging in RPL3 antibody-based research?

The field of RPL3 antibody research continues to evolve, with several promising directions:

• Development of more specific monoclonal antibodies targeting distinct RPL3 epitopes, similar to how researchers have developed highly specific antibodies against viral proteins like those in SARS-CoV-2 .

• Application of RPL3 antibodies in studying ribosomal stress responses and nucleolar dynamics, which could provide insights similar to those gained from studies of T-cell responses using monoclonal antibodies like OKT3 .

• Integration of RPL3 antibody-based techniques with advanced imaging methods such as super-resolution microscopy and expansion microscopy to better understand ribosome distribution and dynamics.

• Standardization of RPL3 antibody validation protocols across laboratories to address reproducibility challenges, following models implemented for other antibodies .

• Development of multiplex detection systems that can simultaneously analyze RPL3 alongside other ribosomal proteins and translation factors.

The continuous improvement in antibody characterization methodologies, as demonstrated in standardized antibody evaluation studies, will further enhance the reliability and utility of RPL3 antibodies in diverse research applications .